Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
about
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysisGenetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International SitesEpidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast BrazilHIV-1 drug resistance and resistance testing.HIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Global trends in molecular epidemiology of HIV-1 during 2000-2007.Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data.Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in SwedenThe influence of HIV-1 subtypes C, CRF31_BC and B on disease progression and initial virologic response to HAART in a Southern Brazilian cohort.Prevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaHIV-1 antiretroviral resistance: scientific principles and clinical applicationsCOMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integraseDifference in absolute CD4+ count according to CD4 percentage between Asian and Caucasian HIV-infected patientsVirologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Identification and genetic characterization of unique HIV-1 A1/C recombinant strain in South Africa.HIV Genetic Diversity and Drug Resistance.Clinical management of HIV drug resistance.Mechanisms and factors that influence high frequency retroviral recombinationTreatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisThe Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHODComparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug usersMortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceHIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in SpainVirologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaIncreasing HIV subtype diversity and its clinical implications in a sentinel North American populationPrevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural TanzaniaEvaluation of Hologic Aptima HIV-1 Quant Dx Assay on the Panther System on HIV Subtypes.Molecular epidemiology of HIV-1 clades in Southern Brazil.
P2860
Q28471994-09FA002D-9254-4B77-A3CE-836BB2D7BBBDQ28480877-B4B2EAE3-24D2-41B1-A3AA-B05A3CAC3C40Q28550335-1D2E66AB-B08C-4DD4-B81D-C8C675821152Q28552354-7B19B39E-A8BB-49D7-903F-E1BF5DA34355Q30245693-B06C9360-3E40-44D7-B7C2-7850F5D07FFFQ30352010-2C2429B8-7F3B-4DCF-A005-B8E214F204F3Q30354857-5D79812E-9876-41FC-8FE1-4DE21BE6FF0FQ30399382-76B1DC21-ED92-4E99-8334-20D46C70CCEFQ33505354-0BB23B24-449F-498F-B843-B9ECC21A032FQ33683115-40254ADF-2DC2-4A65-994D-CEB0EF01946AQ33850909-76339B07-F0C4-41F0-8E2F-B812F364F37BQ33856712-74778831-EF39-4A4C-90FE-3EAA4E3FD5BAQ33859741-8FEFEB5F-0884-4436-B0B3-F14D81BE7D75Q34116836-7140927C-90CD-4959-8659-77AA977363B4Q34280466-6161E761-9945-4128-8546-F9D2F25A2626Q34312943-8B91B83D-CC8A-491B-8A29-749AD2B96D93Q34597650-459BAA3C-4108-4C8F-89C7-28E9BD09D2AEQ34765992-A8F6F4F8-6FED-448C-8247-71ACA009CE46Q34923677-BCFA939A-8302-47F8-8B0E-BC92954CBF51Q34993070-DECBD608-CCD9-4610-8B64-4528A6D2AFA1Q35105844-0A785804-DE0F-4067-9D62-5944DB19DDC3Q35142500-61AE8924-8C7A-483D-BB4A-1936C89A2B79Q35260590-FF192FC7-A22C-408C-8DDC-8285DC990D74Q35261045-73738BC1-9C4E-42D3-BD42-A573A907C93FQ35276750-83FB3363-87D4-4F84-983F-068D30E8265EQ35827900-CD4CC41C-618F-4051-9180-9A040F9E8DD1Q35880435-93C0DCE8-13FB-45AA-8ECE-7653F2A57707Q35887051-937D6604-2410-4AAA-A7AE-23882DA3254EQ35916153-A629F66E-E77F-4733-8C30-521DE29DAC82Q36250342-1B91572C-3C78-4C29-95F5-CCA3DFC5EF46Q36283432-7E16DA50-BA4F-4AF3-8E69-5B7589C13564Q36458517-D779C36D-5F9E-42A4-9F50-A7550F8571FAQ36501787-1879D631-9B92-4A36-862B-91EFCC84C008Q36588672-C679B067-B239-4295-92A8-FB8A915D778DQ36743921-916F244D-581E-4BE9-A2F5-377A46636098Q37033512-A01736CD-92D9-4162-A8D1-5BF586D4F1BCQ37037315-01D97AA0-FE16-4B41-8553-51C28DE7C102Q37111546-2A80AF13-1D1C-4192-832C-ECE7BD72D901Q37280582-17AB0A64-E03B-4D34-B4EE-D533C7071FFDQ37402465-FFCEA54F-AA62-41B8-97B1-D3AB87BCC6FA
P2860
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@en
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@nl
type
label
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@en
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@nl
prefLabel
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@en
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@nl
P2093
P50
P356
P1476
Effect of HIV-1 subtype on vir ...... active antiretroviral therapy.
@en
P2093
Anna Maria Geretti
David Dunn
Hannah Green
Linda Harrison
Teresa Hill
UK Collaborative Group on HIV Drug Resistance
P304
P356
10.1086/598502
P407
P577
2009-05-01T00:00:00Z